225 related articles for article (PubMed ID: 16954317)
1. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.
Lounis N; Veziris N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
Antimicrob Agents Chemother; 2006 Nov; 50(11):3543-7. PubMed ID: 16954317
[TBL] [Abstract][Full Text] [Related]
2. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
Ibrahim M; Andries K; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V; Veziris N
Antimicrob Agents Chemother; 2007 Mar; 51(3):1011-5. PubMed ID: 17178794
[TBL] [Abstract][Full Text] [Related]
3. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
Ibrahim M; Truffot-Pernot C; Andries K; Jarlier V; Veziris N
Am J Respir Crit Care Med; 2009 Sep; 180(6):553-7. PubMed ID: 19590024
[TBL] [Abstract][Full Text] [Related]
4. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.
Veziris N; Ibrahim M; Lounis N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
Am J Respir Crit Care Med; 2009 Jan; 179(1):75-9. PubMed ID: 18948422
[TBL] [Abstract][Full Text] [Related]
5. [R207910 (TMC207): a new antibiotic for the treatment of tuberculosis].
Lounis N; Guillemont J; Veziris N; Koul A; Jarlier V; Andries K
Med Mal Infect; 2010 Jul; 40(7):383-90. PubMed ID: 19954909
[TBL] [Abstract][Full Text] [Related]
6. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis.
Veziris N; Ibrahim M; Lounis N; Andries K; Jarlier V
PLoS One; 2011 Mar; 6(3):e17556. PubMed ID: 21408613
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
[TBL] [Abstract][Full Text] [Related]
8. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
[TBL] [Abstract][Full Text] [Related]
9. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
Nuermberger E; Tyagi S; Williams KN; Rosenthal I; Bishai WR; Grosset JH
Am J Respir Crit Care Med; 2005 Dec; 172(11):1452-6. PubMed ID: 16151038
[TBL] [Abstract][Full Text] [Related]
10. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
Ji B; Lefrançois S; Robert J; Chauffour A; Truffot C; Jarlier V
Antimicrob Agents Chemother; 2006 Jun; 50(6):1921-6. PubMed ID: 16723546
[TBL] [Abstract][Full Text] [Related]
12. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model.
Lounis N; Gevers T; Van Den Berg J; Andries K
Antimicrob Agents Chemother; 2008 Oct; 52(10):3568-72. PubMed ID: 18644960
[TBL] [Abstract][Full Text] [Related]
13. Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs.
Liang Y; Wu X; Zhang J; Yang Y; Wang L; Bai X; Yu Q; Li N; Li Z
Scand J Immunol; 2011 Jul; 74(1):42-6. PubMed ID: 21352251
[TBL] [Abstract][Full Text] [Related]
14. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.
Andries K; Verhasselt P; Guillemont J; Göhlmann HW; Neefs JM; Winkler H; Van Gestel J; Timmerman P; Zhu M; Lee E; Williams P; de Chaffoy D; Huitric E; Hoffner S; Cambau E; Truffot-Pernot C; Lounis N; Jarlier V
Science; 2005 Jan; 307(5707):223-7. PubMed ID: 15591164
[TBL] [Abstract][Full Text] [Related]
15. [Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)].
Grosset J; Truffot C; Fermanian J; Lecoeur H
Pathol Biol (Paris); 1982 Jun; 30(6):444-8. PubMed ID: 6810288
[TBL] [Abstract][Full Text] [Related]
16. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.
Lenaerts AJ; Hoff D; Aly S; Ehlers S; Andries K; Cantarero L; Orme IM; Basaraba RJ
Antimicrob Agents Chemother; 2007 Sep; 51(9):3338-45. PubMed ID: 17517834
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
Alvirez-Freites EJ; Carter JL; Cynamon MH
Antimicrob Agents Chemother; 2002 Apr; 46(4):1022-5. PubMed ID: 11897584
[TBL] [Abstract][Full Text] [Related]
19. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Rustomjee R; Lienhardt C; Kanyok T; Davies GR; Levin J; Mthiyane T; Reddy C; Sturm AW; Sirgel FA; Allen J; Coleman DJ; Fourie B; Mitchison DA;
Int J Tuberc Lung Dis; 2008 Feb; 12(2):128-38. PubMed ID: 18230244
[TBL] [Abstract][Full Text] [Related]
20. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.
Veziris N; Truffot-Pernot C; Aubry A; Jarlier V; Lounis N
Antimicrob Agents Chemother; 2003 Oct; 47(10):3117-22. PubMed ID: 14506018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
